CAPMATINIB TAB
Clinical Criteria Summary
Exclusion Criteria
- EGFR mutation (exon 19 or exon 21 mutation) or ALK rearrangement
- Neurologically unstable CNS metastases
- Unmanageable Strong or Moderate CYP3A4 inducer drug interaction identified
- Current interstitial lung disease or interstitial pneumonitis including radiation pneumonitis
- Creatinine clearance < 30 mL/min
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding
Inclusion Criteria
- Care is provided by a VA/VA purchased care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented
- Female patients of child-bearing potential or male with female partner of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment; use effective contraception during therapy and for 1 week after the last dose
- Additional Inclusion Criteria (at least one must be fulfilled)
- Patient with metastatic non-small cell lung cancer whose tumor has a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test
- Patient-specific recommendation for capmatinib from the National Precision Oncology Program for the minimal duration needed to assess for efficacy (in most cases 8-12 weeks)